Enabling aerosol delivery of phages to defeat antibiotic-resistant bacteria

该项目旨在探索使用噬菌体生产安全，天然和高效的传统抗生素替代品。由多重耐药革兰氏阴性菌引起的呼吸道感染是全球范围内的一个主要健康问题，每年给澳大利亚造成的损失超过1.5亿美元。每年约有5,000名澳大利亚人死于抗生素耐药性感染。该项目的目的是生产有效和稳定的噬菌体制剂，易于作为气溶胶吸入，具有较长的保质期，使其成为商业上可行的产品。预期的研究结果可以导致一个经济和有效的技术，以生产噬菌体粉末的新的治疗策略的感染通过吸入。

This project aims to explore the use of bacteriophages towards producing a safe, natural, and highly effective alternative to traditional antibiotics. Respiratory infections caused by multidrug-resistant Gram-negative bacteria are a major health problem worldwide, and cost Australia over $150 million annually. Some 5,000 Australians die each year from antibiotic resistant infections. The project aims to produce efficacious and stable formulations of bacteriophages for easy delivery by inhalation as aerosols with a long shelf-life, making them a commercially viable product. The expected research outcome can lead to an economic and efficient technology to produce phage powders for novel treatment strategies of infections by inhalation.